First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis.

Wentao TianLishui NiuYin ShiShuishi LiRongrong Zhou

Published in: Therapeutic advances in medical oncology (2024)

Although PembroC has the optimal efficacy, NivoIpiC and AteC were the most favorable treatments in terms of cost-effectiveness for patients with advanced non-squamous NSCLC from the US and Chinese perspectives, respectively.

Keyphrases

systematic review
high grade
low grade
small cell lung cancer
meta analyses
advanced non small cell lung cancer
randomized controlled trial
case control
epidermal growth factor receptor
brain metastases
network analysis
chemotherapy induced